PrednisoneRebound effect manifesting as worsening of COVID-19 following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1938卷 / 1期

关键词：

D O I：

10.1007/s40278-023-31244-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1103 / 1103

相关论文

共 50 条

[1] PrednisoneRebound effect manifesting as worsening of proteinuria: case report
[J]. Reactions Weekly, 2021, 1837 (1) : 594 - 594
[2] ModafinilMuscular pain worsening following off-label use: case report
[J]. Reactions Weekly, 2022, 1925 (1) : 323 - 323
[3] BevacizumabProteinuria and worsening of hypertension following an off-label use: case report
[J]. Reactions Weekly, 2022, 1916 (1) : 104 - 104
[4] TocilizumabInfection and worsening of pre-existing COVID-19 symptoms following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1841 (1) : 227 - 227
[5] Multiple drugsPancytopenia, COVID-19 and off-label use: case report
[J]. Reactions Weekly, 2020, 1831 (1) : 209 - 209
[6] Lopinavir/ritonavirAcute hepatocellular hepatitis following off-label use in COVID-19: case report
[J]. Reactions Weekly, 2020, 1828 (1) : 302 - 302
[7] Ipilimumab/nivolumabVitiligo and worsening of hypothyroidism following off-label use: case report
[J]. Reactions Weekly, 2021, 1886 (1) : 238 - 238
[8] TocilizumabViral myocarditis, increased viral replication and worsening of COVID-19 following off-label use: 2 case reports
[J]. Reactions Weekly, 2020, 1813 (1) : 220 - 220
[9] Dexamethasone/rituximabWorsening of COVID-19 pneumonia and off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 248 - 248
[10] Multiple drugsLack of efficacy and off-label use in COVID-19: case report
[J]. Reactions Weekly, 2022, 1914 (1) : 317 - 317

← 1 2 3 4 5 →